Pharsight

Pierre Fabre Derma patents expiration

1. Hemangeol patents expiration

HEMANGEOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338489 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(5 years from now)

US8987262 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(5 years from now)

Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient

Market Authorisation Date: 14 March, 2014

Treatment: Method to treat hemangioma.; Method to treat infantile hemangioma

Dosage: SOLUTION;ORAL

How can I launch a generic of HEMANGEOL before it's drug patent expiration?
More Information on Dosage

HEMANGEOL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic